EpimAb Biotherapeutics and Almirall announced a license agreement on the development of bispecific antibodies for up to three undisclosed target pairs.
EpimAb Biotherapeutics and Almirall announced a license agreement on the development of bispecific antibodies for up to three undisclosed target pairs.